Trandolapril is an ACE (Angiotensin-Converting Enzyme) inhibitor used to treat high blood pressure (hypertension) and improve survival after a heart attack. It may also be prescribed for other cardiovascular conditions. Trandolapril is a prodrug that must be metabolized into its active form, trandolaprilat, to exert its therapeutic effects. Structurally, it is similar to ramipril but features a cyclohexane group, which contributes to its unique pharmacokinetic properties.
Parent: Enalapril / Trandolapril/ Ramipril/ Quinapril / Spirapril/ Moexipril/ Enalaprilat
Parent: Trandolapril
Parent: Trandolapril
Parent: Trandolapril
Parent: Trandolapril
Parent: Trandolapril
Parent: Trandolapril
Parent: Trandolapril
Impurities in Trandolapril can arise due to synthesis processes, degradation, or storage conditions. Regulatory authorities like the FDA, ICH, and EMA enforce strict impurity limits to ensure the drug’s safety and efficacy.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Common adverse reactions to trandolapril include cough, dizziness, fatigue, hypotension, and elevated potassium levels (hyperkalemia). In rare cases, it may cause angioedema or renal impairment.
Trandolapril can be taken once daily, preferably at the same time each day, with or without food. Consistency helps maintain stable blood levels of the medication.
The duration of action of trandolapril can last up to 24 hours due to its active metabolite, trandolaprilat, which has a prolonged half-life.
Trandolapril is contraindicated in patients with a history of angioedema related to ACE inhibitors, pregnancy, severe renal impairment, and bilateral renal artery stenosis. It should also be avoided in patients hypersensitive to ACE inhibitors.
